Ms. Ge is a Master's candidate in Pharmaceutics at Nanjing University of Chinese Medicine, under the supervision of Professor Yiwei Wang. Her research focuses on innovative drug delivery systems for reproductive health, dedicated to developing patient-centric long-acting contraceptive technologies. Her core achievement is an injectable biodegradable hydrogel platform. Through precise control of polymer networks, it achieves >90% drug encapsulation efficiency and maintains stable plasma drug concentrations for over 20 days in rodent models. She innovatively combines material synthesis with in vitro permeability evaluation to significantly enhance the bioavailability of hormonal contraceptives while reducing their side effects. This research bridges modern pharmaceutical engineering with global family planning needs, providing a breakthrough solution for long-acting contraceptive systems. Her presentation will detail the platform's design principles and preclinical validation data, demonstrating its "low-frequency dosing" technological advantage.

Dr Jared Miles is a proud Yuwi man, pharmacist and early-career researcher with interests spanning from culturally safe and effective pharmacy practice through to new technologies for pharmaceutical development and delivery. After graduating from UQ with a Bachelor of Pharmacy (Honours) in 2012, he worked as a community pharmacist before returning to undertake a PhD in pharmaceutical sciences. Jared is currently a Senior Lecturer with UQ School of Pharmacy and Pharmaceutical Sciences, and also works as a clinical and research pharmacist with the Institute of Urban Indigenous Health (IUIH).

Dr. Hudson Polonini is a pharmacist with a PhD in Pharmaceutical Sciences. He currently serves as Global R&D Manager at Fagron BV in Rotterdam, where he leads the development of personalized pharmaceutical formulations. Dr. Polonini has authored over 110 peer-reviewed publications and holds expertise in drug stability, nanotechnology, and transdermal delivery systems. He has also held academic positions, including professorship at Federal University of Juiz de Fora (Brazil). Dr. Polonini's work bridges academic research and industrial application, contributing significantly to the advancement of personalized medicine.

Dr. Anke de Leeuw is a Field Application Engineer at REGENHU, where she supports researchers in adopting advanced bioprinting technologies for tissue engineering and regenerative medicine. She holds a PhD in Biomedical Sciences from ETH Zürich, where her research—conducted in collaboration with the Children’s Hospital Zürich—focused on developing 3D-printed, patient-specific bone organoids to study rare skeletal diseases. Her work combined biofabrication, biomechanics, and transcriptomics to model osteogenesis imperfecta in vitro and investigate treatment strategies. Anke has extensive experience in 3D cell culture, biological data analysis, and bioink development, and she has authored multiple scientific publications in the field. At REGENHU, she leverages this interdisciplinary background to help laboratories worldwide design and optimize complex bioprinting workflows, from material preparation to functional tissue models. Passionate about translational science, Anke plays a key role in bridging cutting-edge research with practical application, enabling the development of next-generation models for drug discovery and personalized medicine.

Ms. Dung Pham-Thi-Ngoc is an emerging researcher focused on recombinant protein expression and molecular immunology techniques. In her work titled Generation of therapeutic and diagnostic recombinant proteins in the periplasm of Escherichia coli W3110 ΔompC, she has contributed thoughtfully to the design and development of expression systems for proinsulin and the nanobody NTV1. Drawing upon a solid foundation in molecular biology and practical experience, Ms. Pham-Thi-Ngoc strives to bridge the gap between fundamental research and translational applications, aiming to advance meaningful diagnostic and therapeutic solutions. She values opportunities for collaboration and exchange with fellow scientists to foster continued innovation in the biotechnology field.

Mr. Christopher Busayo Olowosoke is a distinguished scholar, entrepreneur, and researcher. He is the founder and CEO of B.Khrease Academic Consult, research fellow at the Institute of Bioinformatics and Molecular Therapeutics (IBMT) and the Computer-aided Therapeutic Discovery and Design Platform (CATDD), where he actively contributes to advancements in biotechnology and drug discovery research. Christopher is affiliated with other professional organizations and his work have earned him multiple prestigious awards and grants, including recognition from the UNESCO-International Centre for Biotechnology under the Food and Health Security thematic area in 2021, the American Society for Nutrition Early Career Scientists (ASN-ECS) on Professional Development in 2022, and the New Frontiers in Research Fund on International Joint Initiative for Research in Climate Change Adaptation and Mitigation in 2023. His scholarly achievements extend to authoring and co-authoring numerous publications related to drug discovery for human disease and initiatives aimed at enhancing student writing skills.